The proposal builds on innovative technologies patented and published by my group. The project has two specific objectives: 1) to deliver the new generation of intelligent biomedical devices that have the capacity to control infections, inflammation and foreign body response; and 2) to develop a novel, non-invasive and affordable point of care diagnostic technology for early detection of chronic kidney diseases, and kidney and bladder cancers that is much needed in this space of healthcare.
Optimising Patient Outcomes Following Surgery: Bridging The Fields Of Antimicrobial Stewardship, Microbiology And Infection Prevention
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
Over 2.4 million surgeries are performed yearly in Australia. Up to 15% of procedures are complicated by infection leading to patient suffering. These infections are also implicated in the emergence of antibiotic resistance. My research will help us understand how infections develop, how to prevent these infections and how to incorporate best-practice into patient care. My research will bridge these key areas to help improve outcomes for patients undergoing surgical procedures.
Defining The Roles Of The Chemotactic Receptor EBI2 For The Regulation Of Leukocyte Migration And The Generation Of Immunity
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
The proposed study aims at improving our understanding of the role of the immune cell receptor Epstein-Barr virus-induced gene 2 (EBI2) in guiding the movement of white blood cells during immune responses. The project will investigate the function of EBI2 in the control of infectious diseases and its regulation on human immune cells. These insights have the potential to create new therapeutic approaches to treat human autoimmune and inflammatory diseases and improve vaccine design.
Long Lived, Virus Resistant Resident Memory T Cells
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
Vaccines that deposit memory T cells within the lung, gut and genital tract hold enormous therapeutic potential, as these mucosal surfaces are major portals of entry into the body for many viruses. However, the accumulation of large numbers of T cells within the mucosal tissue may increase the number of target cells for T cell trophic viruses (eg HIV) to infect. We will explore factors that are important in the generation of mucosal memory T cells that are also resistant to virus infection.
DNA sequencing allows us to see into the microbial world in fine detail. This enables us to investigate how bugs like bacteria cause infections and other diseases. In this fellowship, I will use DNA sequencing and analysis to investigate how bacterial infections are transmitted in hospitals and cities, how bacteria become resistant to the antibiotic drugs we use to treat infected people, and how the bacteria that live in our nose and throat contribute to development of asthma in young children.
Immune Balance-regulating Interleukins As Targets For Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
The immune balance is crucial to human health. Interleukins are a group of proteins secreted by immune cells to mediate their communication. They tune up or down immune responses, thus as attractive targets for immunotherapy to restore the immune balance to treat autoimmune diseases, allergies and infections. This fellowship will support translational research to develop Interleukin-2 (IL-2) and IL-21-based novel immunotherapies for autoimmune disease, infection and allergy.
New Strategies To Guide Tuberculosis Elimination In High And Low-prevalence Settings
Funder
National Health and Medical Research Council
Funding Amount
$262,220.00
Summary
Tuberculosis (TB) is a bacterial disease that affects more than 10 million people worldwide each year. Dr Fox is clinical trialist with a rapidly growing international profile and demonstrated capacity to lead multi-centre studies in Asia. During this Fellowship, he will lead six studies - three in Australia and three in Vietnam –aiming to reduce the impact of TB among high-risk populations.
Enhanced Translation Of Epstein-Barr Virus Nuclear Protein, EBNA1, As A Target Fot T Cell-based Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$380,558.00
Summary
Epstein-Barr virus, (EBV) is a human herpesvirus associated with a range of human cancers. EBNA1, an important EBV antigen, was thought to be “immunologically silent” however, recent studies from our laboratory show that EBNA1 is recognized by our body's defence system and these observations raise the possibility that EBNA1 may be an exploitable, immuno-therapy target for treating EBV-associated cancers.
Genomic-based Tools To Support The Control Of Urogenital Schistosomiasis And Hepatic Opisthorchiasis
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
Over 100 million people are affected by parasitic flukes that promote malignant tumours. Parasite control depends on a single drug, making resistance an imminent threat. I will deliver new genomic tools to unravel the complex interactions between parasites and humans, and explore parasite population diversity on a continental scale. I will then prioritise a panel of anti-parasitic drug targets and vaccine candidates to deliver the next generation of interventions against parasitic diseases.
Proteomic Approaches To Explore The Pathogenesis And Secretomes Of Parasitic Flukes Of Humans
Funder
National Health and Medical Research Council
Funding Amount
$415,320.00
Summary
Ten percent of the human population are at risk of infection with liver, blood and lung flukes. These parasites cause considerable human morbidity and mortality including a strong association with cancer of the bile ducts. Current control efforts rely on drugs, but, reinfection and resistance are a problem. This research is aimed at understanding how these parasites cause disease (particularly how a parasite causes cancer) and the development of vaccines and new drugs.